Nuvastatic ™ is a high dose formulation of Cat Whiskers leaves Lanctos 75 extract. The product contains 1000mg of the extract that is formulated with NatureCeuticals patented Protaste TM formulation.
Nuvastatic is presented as an effervescence drink dosage form. Currently the product is undergoing clinical studies for cancer asthenia (fatigue) and also as treatment agent for breast cancer and colon cancer.
Nuvastatic TM has completed its preclinical safety pharmacology , phase 1 clinical studies and currently undergoing phase 2/3 clinical studies for cancer asthenia and phase 2 clinical studies for breast and colon cancer.
Nuvastatic TM is expected to complete its phase 3 clinical studies before the end of 2018. The phase 3 USFDA clinical studies is expected to commence by the 3rd quarter 2018 and ends by 2nd quarter 2020.
If successful Nuvastatic TM will be the first herbal based drug in the world approved by the USFDA for cancer treatment.
Nuvastatic TM is currently undergoing Phase 2 clinical studies for breast cancer and colon cancer. The drug is given to newly diagnosed stage 3 or 4 breast colon cancer while undergoing chemotherapy. The clinical studies aims to show that the patients taking Nuvastatic TM with chemotherapy has a better progression free survival (PFS) compared to patients undergoing chemotherapy alone. The angiogenesis inhibition activity of Nuvastatic TM is expected to slow or halt the disease progression of the cancer patients. Nuvastatic TM also inhibits the expression of a gene that codes a receptor known as the MDR (Multi Drug Receptor) that causes resistance to chemotherapy. It is expected that Nuvastatic TM to have beneficial effect on breast cancer and colon cancer sufferers.